Pharmacyte Biotech Inc (PMCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 04/30
| 04-2015 | 04-2014 | 04-2013 | 04-2012 | 04-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,928 | -27,254 | -1,598 | -1,899 | -1,398 |
| Depreciation Amortization | N/A | N/A | -6 | 14 | 30 |
| Accounts receivable | N/A | N/A | 3 | -7 | -1 |
| Accounts payable and accrued liabilities | 309 | -59 | 98 | 174 | 31 |
| Other Working Capital | 1,741 | -484 | 365 | 239 | 166 |
| Other Operating Activity | 3,317 | 26,242 | 749 | 1,220 | 947 |
| Operating Cash Flow | $-4,560 | $-1,555 | $-390 | $-259 | $-225 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | 3 | N/A |
| Net Acquisitions | N/A | -51 | N/A | -874 | N/A |
| Purchase Sale Intangibles | N/A | -3,500 | -647 | N/A | N/A |
| Other Investing Activity | 0 | -3,508 | -647 | 0 | 0 |
| Investing Cash Flow | $N/A | $-3,559 | $-647 | $-872 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 82 | 150 | 1,194 | 117 |
| Debt Repayment | -144 | -62 | -75 | -125 | N/A |
| Common Stock Issued | 3,786 | 8,511 | 1,146 | 21 | 100 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 64 |
| Financing Cash Flow | $3,642 | $8,531 | $1,221 | $1,090 | $282 |
| Exchange Rate Effect | 2 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 3,617 | 199 | 16 | 57 | 1 |
| End Cash Position | 2,700 | 3,617 | 199 | 16 | 57 |
| Net Cash Flow | $-917 | $3,417 | $184 | $-42 | $57 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,560 | -1,555 | -390 | -259 | -225 |
| Free Cash Flow | -4,560 | -1,555 | -390 | -259 | -225 |